May 2009- Volume 5, Issue 5
In this Issue
Genomics & Proteomics
Heart of the matter
Heart of the matter
Absorption Systems and ChanTest team up to enhance ADME suite with tests that assess drugs’ risks for unintended cardiac effects
Putting their brains together
Putting their brains together
Gene Network Sciences and M.D. Anderson sic translational medicine on glioblastoma
Catalog of human variation
Catalog of human variation
Applied Biosystems, TGen team up to hasten advent of personalized medicine
Primordial biomarker
Primordial biomarker
Galectin-3 discovery may lead to new cancer treatments
HGS, Morphotek take aim at genomics-derived targets
HGS, Morphotek take aim at genomics-derived targets
The two companies will collaborate to discover, develop and commercialize antibodies for oncology and immunology
A new chapter in genomics research
A new chapter in genomics research
Clinical Data's Cogenics division goes to Beckman Coulter in a deal worth $17 million
Research & Development
Salk Institute signs R&D pact with sanofi-aventis
Salk Institute signs R&D pact with sanofi-aventis
Collaborative agreement supports cutting-edge research, sets stage for rapid advances
MS research takes fast step forward
MS research takes fast step forward
Fast Forward and EMD Serono collaborate on treatments for multiple sclerosis
Live from New York, it’s HIV cell-to-cell transfer
Live from New York, it’s HIV cell-to-cell transfer
Mt. Sinai, UC Davis researchers capture HIV transfer on video
Stem cell therapy for hearing loss?
Stem cell therapy for hearing loss?
Sheffield University team grows stem cells into auditory cells that might one day restore hearing to the deaf
The ‘father of microarrays’ attacks Parkinson’s
The ‘father of microarrays’ attacks Parkinson’s
Arrayit and the Parkinson's Institute announce new research collaboration
Cancer-fighting deal easy as ADC
Cancer-fighting deal easy as ADC
Millennium pays $4 million to Seattle Genetics in antibody-drug conjugate collaboration
Red ribbon allies
Red ribbon allies
GSK and Pfizer merge HIV businesses to create global joint venture
Automation & Instrumentation
Working even closer
Working even closer
Waters Corp. and University of Warwick turn decades-long relationship into major deal to advance adoption of novel MS technology
Systems biology meets technology
Systems biology meets technology
Agilent Technologies and the University of Michigan join forces to stymie cell metastasis
Top-down proteomics research
Top-down proteomics research
Bio-Rad and Bruker partner to offer new solutions for biomarker discovery and development
Bacteria biosensor makes its debut across the pond
Bacteria biosensor makes its debut across the pond
Abbott grants LGC Europe’s first T5000 Biosensor System license
Seahorse decides to make a splash
Seahorse decides to make a splash
Company acquires BioProcessors and SimCell biomanufacturing technology
Biotechs buying in bulk
Biotechs buying in bulk
Massachusetts Biotechnology Council in $250 million deal with Fisher Scientific to support supply needs of the commonwealth's biotechs
Global News
ACADIA-Meiji Seika Kaisha deal seeks gain without the pain
ACADIA-Meiji Seika Kaisha deal seeks gain without the pain
ACADIA Pharmaceuticals Inc. and Meiji Seika Kaisha Ltd. announced in April their collaboration to develop and commercialize a novel class of pro-cognitive drugs called PCAPs to treat patients with schizophrenia and related disorders.
Dalhousie researchers hit paydirt with discovery
Dalhousie researchers hit paydirt with discovery
A group of Canadian researchers has pinpointed a common virus that could provide a new and effective approach to eliminating breast cancer stem cells—a key tool in the battle against the deadly disease.
Galapagos, Merck sign inflammatory disease agreement
Galapagos, Merck sign inflammatory disease agreement
Partnership on small molecule drug candidates could be worth up to $257 million
Getting closer to the heart
Getting closer to the heart
Lilly forges cardiovascular research collaboration with India's Zydus Cadila worth up to $300 million
An eye for the deal
An eye for the deal
Sanofi-aventis marches south of the border and beyond
Planting the seeds for R&D
Planting the seeds for R&D
MRC and MRC Technology launch new research center in U.K.
Informatics
On the path of personalized medicine
On the path of personalized medicine
TcLand Expression taps Genedata's informatics solutions to strengthen its gene expression data
Bringing on the heat
Bringing on the heat
UCSC Cancer Genomics Browser uses ‘heatmaps’ to visually represent genomic and clinical data side by side
Electronic enterprise-level insight
Electronic enterprise-level insight
Thermo Fisher, Symyx Technologies offer enterprise-level, electronic lab notebook
Genologics’ LIMS forms SOLiD link
Genologics’ LIMS forms SOLiD link
GenoLogics teams up with Applied Biosystems to provide an integrated lab and data management solution for the SOLiD System
Biotech companies mix and match
Biotech companies mix and match
Merger of Eureka and Nanobac to provide a creative way to infuse cash into bioinformatics work and more
Commentary
Commentary: Biotech industry must adapt to changing political and economic landscape
Commentary: Biotech industry must adapt to changing political and economic landscape
A new presidential administration and a new Congress—not to mention the ever-changing economic situation on Wall Street and in financial centers around the world—are testing the speed at which biotechnology companies can react and adapt to the evolving environment.
There is no place for humor in science
There is no place for humor in science
A decade ago, I was given the above instruction by British colleagues in response to an advertisement of my company’s products that used humor to attract attention.
Editor's Focus
Lessons from AACR: Time is greatest obstacle in cancer treatment
Lessons from AACR: Time is greatest obstacle in cancer treatment
Last month, I headed to Denver with the rest of my DDN colleagues to attend the AACR's 100th Annual Meeting, eager to learn about the latest developments in oncology research. But during my last few hours in Denver, my bubble of optimism was pricked by deflating reality.
